Literature DB >> 29364275

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells.

Nouran S Abdelfattah1, Ann Mullally2.   

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) is an adaptive immunity system in prokaryotes that has been repurposed by scientists to generate RNA-guided nucleases, such as CRISPR-associated (Cas) 9 for site-specific eukaryotic genome editing. Genome engineering by Cas9 is used to efficiently, easily and robustly modify endogenous genes in many biomedically-relevant mammalian cell lines and organisms. Here we show an example of how to utilize the CRISPR/Cas9 methodology to understand the biological function of specific genetic mutations. We model calreticulin (CALR) mutations in murine interleukin-3 (mIL-3) dependent pro-B (Ba/F3) cells by delivery of single guide RNAs (sgRNAs) targeting the endogenous Calr locus in the specific region where insertion and/or deletion (indel) CALR mutations occur in patients with myeloproliferative neoplasms (MPN), a type of blood cancer. The sgRNAs create double strand breaks (DSBs) in the targeted region that are repaired by non-homologous end joining (NHEJ) to give indels of various sizes. We then employ the standard Ba/F3 cellular transformation assay to understand the effect of physiological level expression of Calr mutations on hematopoietic cellular transformation. This approach can be applied to other genes to study their biological function in various mammalian cell lines.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29364275      PMCID: PMC5908454          DOI: 10.3791/56726

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  22 in total

Review 1.  RNA-guided genetic silencing systems in bacteria and archaea.

Authors:  Blake Wiedenheft; Samuel H Sternberg; Jennifer A Doudna
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

2.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

3.  Generation of genomic deletions in mammalian cell lines via CRISPR/Cas9.

Authors:  Daniel E Bauer; Matthew C Canver; Stuart H Orkin
Journal:  J Vis Exp       Date:  2015-01-03       Impact factor: 1.355

4.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

6.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Authors:  Shannon Elf; Nouran S Abdelfattah; Edwin Chen; Javier Perales-Patón; Emily A Rosen; Amy Ko; Fabian Peisker; Natalie Florescu; Silvia Giannini; Ofir Wolach; Elizabeth A Morgan; Zuzana Tothova; Julie-Aurore Losman; Rebekka K Schneider; Fatima Al-Shahrour; Ann Mullally
Journal:  Cancer Discov       Date:  2016-03-07       Impact factor: 39.397

Review 7.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

Authors:  Thomas Gaj; Charles A Gersbach; Carlos F Barbas
Journal:  Trends Biotechnol       Date:  2013-05-09       Impact factor: 19.536

8.  Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.

Authors:  Dirk Heckl; Monika S Kowalczyk; David Yudovich; Roger Belizaire; Rishi V Puram; Marie E McConkey; Anne Thielke; Jon C Aster; Aviv Regev; Benjamin L Ebert
Journal:  Nat Biotechnol       Date:  2014-06-22       Impact factor: 54.908

9.  Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.

Authors:  Kevin Watanabe-Smith; Jamila Godil; Anupriya Agarwal; Cristina Tognon; Brian Druker
Journal:  Oncotarget       Date:  2017-02-21

10.  Easy quantitative assessment of genome editing by sequence trace decomposition.

Authors:  Eva K Brinkman; Tao Chen; Mario Amendola; Bas van Steensel
Journal:  Nucleic Acids Res       Date:  2014-10-09       Impact factor: 16.971

View more
  2 in total

1.  Diallyl disulfide down-regulates calreticulin and promotes C/EBPα expression in differentiation of human leukaemia cells.

Authors:  Jing Sun; Hongxiang Mu; Jia Yu; Linwei Li; Hongxia Yan; Guoqing Li; Hui Tan; Nanyang Yang; Xiaoyan Yang; Lan Yi
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

2.  CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.

Authors:  Kathrin Olschok; Lijuan Han; Marcelo A S de Toledo; Janik Böhnke; Martin Graßhoff; Ivan G Costa; Alexandre Theocharides; Angela Maurer; Herdit M Schüler; Eva Miriam Buhl; Kristina Pannen; Julian Baumeister; Milena Kalmer; Siddharth Gupta; Peter Boor; Deniz Gezer; Tim H Brümmendorf; Martin Zenke; Nicolas Chatain; Steffen Koschmieder
Journal:  Stem Cell Reports       Date:  2021-10-21       Impact factor: 7.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.